Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36751 ___________________ ...

Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: May 2021 Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, produc ...

Ocugen, Inc. (NASDAQ:OCGN) Q1 2021 Earnings Conference Call May 7, 2021 9:00 AM ET Company Participants Lisa DeScenza – Vice President-Integrated Communications-LaVoie Health Science Shankar Musunuri – Chairman, Chief Executive Officer and Co-Founder Sanjay Subramanian – Chief Financial Officer and Head-Corporate Development Conference Call Participants Keay Nakae – Chardan Zegbeh Jallah – ROTH Capital Robert LeBoyer – Noble Capital Swayampakula Ramakanth – H.C. Wainwright Kristen Kluska – Cantor Fitzgerald ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36751 __________________ ...

Ocugen, Inc. (NASDAQ:OCGN) Q4 2020 Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants Lisa DeScenza – Vice President of Integrated Communications, LaVoie Health Science Shankar Musunuri – Chairman and Chief Executive Officer Sanjay Subramanian – Chief Financial Officer and Head of Corporate Development Conference Call Participants Keay Nakae – Chardan Zegbeh Jallah – ROTH Capital Partners Swayampakula Ramakanth – H.C. Wainwright Operator Good morning, and welcome to the Ocugen Conferenc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-K ___________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36751 _______________________ ...

Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: March 2021 Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, prod ...

Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to fight COVID-19 NASDAQ: OCGN Corporate Deck: January 2021 Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, product appr ...

收入和利润 - 公司2020年前九个月总收入为4.3万美元，全部来自合作收入，而2019年同期无收入[163][164] - 净亏损从2019年同期的3262万美元改善至1803万美元，减亏1459万美元[163] - 公司净亏损2020年前九个月为1800万美元，2019年同期为3260万美元[144] 研发费用 - 研发费用2020年第三季度为147.7万美元，同比增长17.1万美元[156][157] - 研发费用减少158万美元（同比下降24.9%），主要因OCU310临床试验终止[163][165] - 流程中研发费用2020年第三季度新增700万美元，主因NeoCart资产重分类[156][158] - 新增700万美元在研研发费用，源于NeoCart资产不再符合持有待售分类标准[163][166] 一般行政和管理费用 - 一般行政费用2020年第三季度为170.5万美元，同比增长29.7万美元[156][158] - 行政管理费用增加221万美元（同比增长62.3%），主因保险费增加80万美元[163][166] 重组和遣散费用 - 遣散相关费用2020年前九个月达110万美元，其中研发部门占90万美元[152] - 裁员措施预计从2021年起每年节省200万美元成本[152] 其他费用和收益 - 衍生负债公允价值变动2019年第三季度造成1851.2万美元损失，2020年同期为零[156][159] - 利息支出2020年第三季度为29.2万美元，同比减少50.4万美元[156][160] 现金和融资活动 - 期末现金及受限现金为1930万美元，累计赤字达6950万美元[171][173] - 截至2020年9月30日，公司累计赤字为6950万美元，现金及受限现金余额为1930万美元[144] - 通过ATM发行融资获得净收益2560万美元，总发行8620万股普通股[172] - 经营活动现金流净流出1043万美元，投资活动现金流净流出5.6万美元[174][175] - 未偿还债务包括PPP贷款40万美元及EB-5项目贷款150万美元[178][181] 持续经营风险和预警 - 公司预警1930万美元现金无法满足未来12个月运营需求，正寻求融资方案[183] - 公司对持续经营能力存在重大疑虑[185] - 公司预计需增加支出以继续开发产品[185] - 公司列举多项成本风险因素包括临床试验、监管审批、生产商业化等[185] - 公司提及专利诉讼和知识产权争议防御成本[185] - 公司面临基础设施扩张及上市公司运营相关成本增加[185] - 公司可能涉及产品/技术授权引进或收购相关成本[185] 公司运营和资产状况 - 公司目前无商业化产品，所有资产位于美国宾夕法尼亚州[144][145] - 公司确认无表外安排[187] - 公司采用新会计准则情况参见财务报表附注2[188] - 公司市场风险披露不适用[190] - 公司无其他信息需披露[189]

Ocugen, Inc. (NASDAQ:OCGN) Q2 2020 Results Conference Call August 14, 2020 8:30 AM ET Company Participants Lisa DeScenza - VP of Integrated Communications, LaVoie Health Science Shankar Musunuri - Chairman and CEO Sanjay Subramanian - CFO Mohamed Genead - Acting CMO and Chair of Scientific Advisory Board Conference Call Participants Keay Nakae - Chardan Ramakanth Swayampakula - H.C. Wainwright Kristen Kluska - Cantor Fitzgerald Operator Good morning and welcome to the Ocugen Conference Call. [Operator Instr ...